Novel immune therapeutic tools are rapidly expanding the anticancer arsenal. Despite this progress, patients with colorectal cancer (CRC) that spreads to vital parts of the body still have a dismal outcome. Transforming growth factor-β (TGF-β) plays a pivotal role in the development of CRC and metastasis. Important new work by Tauriello and colleagues has revealed that inhibition of TGF-β prevents tumor metastasis by enhancing a cytotoxic T cell response, suggesting that TGF-β inhibition is a promising pro-immunogenic therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.trecan.2018.03.005 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!